Gamma-aminobutyric acid type A receptor alpha-1 subunit-containing pentamer (GABAAR alpha-1) (GABAAR alpha-1)

The Gamma-aminobutyric acid type A receptor alpha-1 subunit-containing pentamer is the most abundant subtype of ionotropic GABA receptors in the mammalian central nervous system, typically composed of two alpha-1, two beta-2, and one gamma-2 subunits [1.1.1, 1.4.1]. It functions as a ligand-gated chloride channel that mediates fast inhibitory neurotransmission, known as phasic inhibition, by allowing chloride ion influx upon GABA binding, which hyperpolarizes the postsynaptic neuron and reduces its excitability [1.2.1, 1.4.2]. This specific receptor configuration is the primary mediator of the sedative, hypnotic, and anticonvulsant effects of benzodiazepines and Z-drugs like zolpidem, which binds with high affinity to the alpha-1/gamma-2 subunit interface [1.1.1, 1.3.4]. Dysregulation or genetic mutations in the alpha-1 subunit (GABRA1) are associated with various neurological conditions, including juvenile myoclonic epilepsy and other seizure disorders [1.2.1, 1.3.3]. While therapeutically essential for treating insomnia and acute anxiety, targeting these receptors is associated with significant safety concerns such as daytime sedation, ataxia, and the risk of developing tolerance and physical dependence [1.1.2, 1.1.4]. The receptor's widespread distribution in the cortex and hippocampus makes it a critical component of the brain's inhibitory network [1.2.1, 1.4.3]. Chronic modulation of this target can lead to compensatory changes in receptor expression, contributing to the withdrawal symptoms observed with benzodiazepines [1.3.1, 1.3.4]. Recent research also explores its role in neurodevelopment and its potential as a biomarker for certain psychiatric illnesses [1.3.2, 1.3.3].

Other names

BZ1 receptorOmega-1 receptoralpha1-containing GABAA receptorGABRA1-containing pentamerGABAA receptor alpha-1

Positive allosteric modulation of the GABA-A receptor chloride channel